FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213305846> ?p ?o ?g. }

• W3213305846 endingPage "3288" @default.
• W3213305846 startingPage "3288" @default.
• W3213305846 abstract "Abstract Acute myeloid leukemia (AML) is an aggressive malignancy of the blood and bone marrow resulting from the accumulation of multiple serially acquired mutations. The mutational complexity of the disease makes AML difficult to treat, contributing to a low 5-year survival rate. A better understanding of how different mutations interact with one another to influence disease characteristics is critical and may result in the development of targeted therapies to improve patient outcome. The most common recurrent somatic mutation in AML affects the gene NPM1 and occurs in 25-30% of patients. This mutation results in the aberrant cytoplasmic localization of the protein and is termed NPM1cA (Falini et al. 2005, Cancer Genome Atlas Research Network 2013). NPM1cA is considered to be a driver of AML, however Npm1 cA/+ mice only develop disease after a long latency (median 18 months), suggesting that other cooperating mutations are required for AML development (Vassiliou et al. 2011). Approximately 50% of patients with an NPM1cA mutation also harbor a mutation in one of four members of the cohesin complex (STAG2, SMC3, SMC1A, and RAD21). Mutations in cohesin genes are mutually exclusive and result in haploinsufficiency of the complex. As cohesin is known to regulate gene expression by facilitating promoter-enhancer interactions and three-dimensional genome organization, we wished to determine how cohesin mutation influences AML biology and gene expression in the presence of NPM1cA. We utilized the inducible Npm1 cAflox/+ and Smc3 flox/+ mouse models to examine this genetic interaction. We and others have shown that cohesin mutations result in enhanced hematopoietic stem and progenitor cell (HSPC) self-renewal (Mazumdar et al. 2015, Viny et al. 2015, Mullenders et al. 2015, Galeev et al. 2016, Fisher et al. 2017). Consistent with this, Npm1 cA/+;Smc3 Δ/+ HSPCs show enhanced self-renewal in vitro over HSPCs harboring either single mutation. Despite a shared role in self-renewal, Npm1 cA/+;Smc3 Δ/+mice developed AML with similar latency as Npm1 cA/+ mice. Interestingly, however, Npm1 cA/+;Smc3 Δ/+ HSPCs exhibited dysregulation of a unique set of genes compared to cells from either single mutant, suggesting that the Npm1 cA;cohesin mutational combination uniquely alters the transcriptional environment. Further, Npm1 cA/+;Smc3 Δ/+ leukemias had a completely unique spectrum of acquired mutations compared to Npm1 cA/+ leukemias, suggesting that the addition of Smc3 haploinsufficiency to Npm1 cA/+alters AML evolution and that different driver mutations result in the accumulation of very different somatic mutations. Among the uniquely upregulated genes in Npm1 cA/+;Smc3 Δ/+ HSPCs is Dock1, a guanine nucleotide exchange factor (GEF) for Rac1/2. As high Dock1 expression has been associated with low overall and disease-free survival in multiple cohorts of AML patients (Lee et al. 2017, Zhang et al. 2019), we hypothesized that Dock1 would be a novel target for the treatment of Npm1cA; cohesin mut leukemias. Consistent with this hypothesis, We found that knockdown of Dock1 resulted in decreased growth and adhesion and increased apoptosis in an Npm1 cA/+;Smc3 Δ/+leukemic line, but not in an Npm1 cAsingle mutant line. Higher Rac activity was also observed in Npm1 cA/+;Smc3 Δ/+ vs. Npm1 cA/+ leukemic lines. We found that DN Rac2 specifically impacted both the growth and apoptosis of an Npm1 cA/+;Smc3 Δ/+line, suggesting that Dock1 functions primarily through Rac2 to regulate survival. Importantly, the Dock1/Rac pathway is specifically targetable in Npm1 cA/+;Smc3 Δ/+ AMLs in vitro and in vivo, as knockdown of Dock1 resulted in prolonged latency in a Npm1 cA/+;Smc3 Δ/+ transplant model and slowed the growth and enhanced apoptosis of an Npm1 cA/+;Smc3 Δ/+, but not an Npm1 cA/+, leukemic line. Further, small molecule inhibitors of Dock and Rac had similar effects. Our results suggest that Dock1/Rac2 represent unique targets for the treatment of patients harboring the NPM1cA;cohesin mutational combination and provide validity to the concept that combinatorial genetics can uncover novel precision oncology targets. Disclosures Vassiliou: Kymab Ltd: Divested equity in a private or publicly-traded company in the past 24 months; STRM.BIO: Consultancy; Astrazeneca: Consultancy." @default.
• W3213305846 created "2021-11-22" @default.
• W3213305846 creator A5012422415 @default.
• W3213305846 creator A5031833096 @default.
• W3213305846 creator A5036613947 @default.
• W3213305846 creator A5037781922 @default.
• W3213305846 creator A5044518913 @default.
• W3213305846 creator A5060946133 @default.
• W3213305846 creator A5070692514 @default.
• W3213305846 creator A5081020822 @default.
• W3213305846 creator A5087392144 @default.
• W3213305846 creator A5091241671 @default.
• W3213305846 date "2021-11-05" @default.
• W3213305846 modified "2023-10-08" @default.
• W3213305846 title "Combinatorial Genetic Uncovers DOCK1/RAC2 As Specific Targets for the Treatment of NPM1;Cohesin Mutated AML" @default.
• W3213305846 doi "https://doi.org/10.1182/blood-2021-148811" @default.
• W3213305846 hasPublicationYear "2021" @default.
• W3213305846 type Work @default.
• W3213305846 sameAs 3213305846 @default.
• W3213305846 citedByCount "0" @default.
• W3213305846 crossrefType "journal-article" @default.
• W3213305846 hasAuthorship W3213305846A5012422415 @default.
• W3213305846 hasAuthorship W3213305846A5031833096 @default.
• W3213305846 hasAuthorship W3213305846A5036613947 @default.
• W3213305846 hasAuthorship W3213305846A5037781922 @default.
• W3213305846 hasAuthorship W3213305846A5044518913 @default.
• W3213305846 hasAuthorship W3213305846A5060946133 @default.
• W3213305846 hasAuthorship W3213305846A5070692514 @default.
• W3213305846 hasAuthorship W3213305846A5081020822 @default.
• W3213305846 hasAuthorship W3213305846A5087392144 @default.
• W3213305846 hasAuthorship W3213305846A5091241671 @default.
• W3213305846 hasBestOaLocation W32133058461 @default.
• W3213305846 hasConcept C104317684 @default.
• W3213305846 hasConcept C115821613 @default.
• W3213305846 hasConcept C127716648 @default.
• W3213305846 hasConcept C2483381 @default.
• W3213305846 hasConcept C2778729363 @default.
• W3213305846 hasConcept C30481170 @default.
• W3213305846 hasConcept C501734568 @default.
• W3213305846 hasConcept C502942594 @default.
• W3213305846 hasConcept C53226629 @default.
• W3213305846 hasConcept C54355233 @default.
• W3213305846 hasConcept C68838962 @default.
• W3213305846 hasConcept C86803240 @default.
• W3213305846 hasConceptScore W3213305846C104317684 @default.
• W3213305846 hasConceptScore W3213305846C115821613 @default.
• W3213305846 hasConceptScore W3213305846C127716648 @default.
• W3213305846 hasConceptScore W3213305846C2483381 @default.
• W3213305846 hasConceptScore W3213305846C2778729363 @default.
• W3213305846 hasConceptScore W3213305846C30481170 @default.
• W3213305846 hasConceptScore W3213305846C501734568 @default.
• W3213305846 hasConceptScore W3213305846C502942594 @default.
• W3213305846 hasConceptScore W3213305846C53226629 @default.
• W3213305846 hasConceptScore W3213305846C54355233 @default.
• W3213305846 hasConceptScore W3213305846C68838962 @default.
• W3213305846 hasConceptScore W3213305846C86803240 @default.
• W3213305846 hasIssue "Supplement 1" @default.
• W3213305846 hasLocation W32133058461 @default.
• W3213305846 hasOpenAccess W3213305846 @default.
• W3213305846 hasPrimaryLocation W32133058461 @default.
• W3213305846 hasRelatedWork W1898985322 @default.
• W3213305846 hasRelatedWork W1981424553 @default.
• W3213305846 hasRelatedWork W2033574449 @default.
• W3213305846 hasRelatedWork W2043199743 @default.
• W3213305846 hasRelatedWork W2141307855 @default.
• W3213305846 hasRelatedWork W2351781254 @default.
• W3213305846 hasRelatedWork W3009206022 @default.
• W3213305846 hasRelatedWork W3032161284 @default.
• W3213305846 hasRelatedWork W3209716189 @default.
• W3213305846 hasRelatedWork W4315629143 @default.
• W3213305846 hasVolume "138" @default.
• W3213305846 isParatext "false" @default.
• W3213305846 isRetracted "false" @default.
• W3213305846 magId "3213305846" @default.
• W3213305846 workType "article" @default.